Patents Assigned to Imperial Innovations Limited
  • Patent number: 10768103
    Abstract: A method of mapping a tissue characteristic in a tissue sample comprises gathering infrared absorption data from the sample at selected wavelengths, and determining, from the infrared absorption data, a first measure of the amount of power or energy absorbed attributable to an amide moiety and a second measure of the amount of power or energy absorbed attributable to a phosphate moiety. A ratio of the first measure and the second measure is used to establish a histological index. The histological index may be used to indicate a malignancy grade of tumour in the tissue.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: September 8, 2020
    Assignee: IMPERIAL INNOVATIONS LIMITED
    Inventors: Christopher Clement Phillips, Hemmel Amrania
  • Patent number: 10756377
    Abstract: There is provided a regenerative fuel cell capable of operating in a power delivery mode in and in an energy storage mode. The cell may comprise a reversible hydrogen gas anode, in an anode compartment, a reversible cathode in a cathode compartment, and a membrane separating the anode compartment from the cathode compartment, which membrane is capable of selectively passing protons. an additive may be provided in the cathode compartment.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: August 25, 2020
    Assignee: Imperial Innovations Limited
    Inventors: Nigel Brandon, Vladimir Yufit, Anthony Kucernak, Javier Rubio-Garcia
  • Publication number: 20200239535
    Abstract: The present invention provides phagemid vectors and associated phagemid particles for cancer treatment, and in particular, to the use of novel phagemid particles and associated expression systems for the treatment, prevention, amelioration, or management of cancer. In particular, the invention relates to the use of phagemid particles and expression systems for the delivery of transgenes encoding cytokines, for the treatment, prevention, amelioration, or management of cancer. The invention also extends to the use of phagemid particles and expression systems for the delivery of transgenes, and for the combination of such treatment with the use of adoptively transferred T cells, for the treatment, prevention, amelioration, or management of cancer.
    Type: Application
    Filed: April 24, 2018
    Publication date: July 30, 2020
    Applicant: Imperial Innovations Limited
    Inventors: Amin Hajitou, Keittisak Suwan, Mariam Albahrani, Sajee Waramit
  • Patent number: 10646600
    Abstract: A method of use of an isolated polypeptide conjugated with a radionuclide, wherein the isolated polypeptide binds specifically to HER2, or a variant thereof is described. The method is for monitoring the response to HSP90 inhibition and comprises the use of the isolated polypeptide conjugated with 18F. The application also describes the use of an isolated polypeptide conjugated with 18F, wherein the isolated polypeptide binds specifically to HER2 or variants thereof, as an imaging agent to monitor uptake thereof to measure HSP90 inhibition.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: May 12, 2020
    Assignees: IMPERIAL INNOVATIONS LIMITED, GE HEALTHCARE LIMITED
    Inventors: Duncan Robert R. Hiscock, Eric Aboagye, Peter Iveson, Quang-De Nguyen, Susan Hoppmann, Sebastian Trousil, Maciej Kaliszczak, Giampaolo Tomasi
  • Patent number: 10624755
    Abstract: A prosthetic glenoid component (10) comprising a concave external bearing surface (12), a glenoid-contacting surface (14) opposite to the bearing surface, and a plurality of fixation elements (16) protruding from said glenoid-contacting surface (14) oppositely to said bearing surface (12) for location into a peripheral portion (104b) of a glenoid cavity (104) to secure the component to the scapula (102), wherein a central portion (15) of the glenoid-contacting surface (14) is free of fixation elements so as to preserve the integrity of the glenoid vault.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: April 21, 2020
    Assignee: Imperial Innovations Limited
    Inventors: Andrew Amis, Diogo Geraldes, Roger John Hart Emery, Ulrich N. Hansen
  • Publication number: 20200017860
    Abstract: The present invention related to identification of therapeutic agents of the treatment, diagnosis, and prevention of pulmonary hypertension.
    Type: Application
    Filed: June 5, 2019
    Publication date: January 16, 2020
    Applicant: IMPERIAL INNOVATIONS LIMITED
    Inventors: Eduardo Oliver-Perez, Lan Zhao, Martin Wilkins, Tim Aitman
  • Patent number: 10502882
    Abstract: There is provided a light source arranged to output light at a first wavelength. The light source comprises a luminescent concentrator having a slab-shaped geometry. The luminescent concentrator comprises: an input port arranged to receive light and define a first area; an output port arranged to transmit light and define a second area which is smaller than the first area; and surfaces arranged to direct light inside the luminescent concentrator to the output port. The luminescent concentrator further comprises lumophores arranged to receive light at a second wavelength and emit light at the first wavelength; and a pump light supply coupled to the input port and arranged to illuminate the input port with light at the second wavelength.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: December 10, 2019
    Assignee: Imperial Innovations Limited
    Inventors: Juna Sathian, Mark Oxborrow
  • Patent number: 10483583
    Abstract: A fuel cell assembly is disclosed comprising a fuel cell electrode component and a reactant gas flow component ink bonded thereto. In one aspect direct bonding of a gas diffusion layer with a flow field is achieved allowing a simplified structural configuration. In another aspect improved component printing techniques reduce corrosion effects. In a further aspect flow fields are described providing reactant channels extending in both the horizontal and vertical directions, i.e. providing three dimensional flow. In a further aspect an improved wicking material allows wicking away and reactant humidification. In a further aspect improved mechanical fastenings and connectors are provided. In a further aspect improved humidification approaches are described. Further improved aspects are additionally disclosed.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: November 19, 2019
    Assignee: Imperial Innovations Limited
    Inventor: Anthony Robert John Kucernak
  • Publication number: 20190343403
    Abstract: An implantable intravascular device for deployment inside a human or animal, the apparatus comprising a body of crystalline material and a membrane of crystalline material fixed to the body by a hermetic bond an assembly of components carried on said crystalline material and arranged for responding to electrical signals wherein the body and the membrane at least partially encapsulate the assembly.
    Type: Application
    Filed: September 20, 2017
    Publication date: November 14, 2019
    Applicant: Imperial Innovations Limited
    Inventors: Mohammad Reza Bahmanyar, Christopher Neil McLeod
  • Publication number: 20190343410
    Abstract: An implantable intravascular pressure sensor comprising a first transducer arranged to provide a pressure dependent signal in response to alternating electrical signals of a first frequency band, a second transducer arranged to provide a reference signal in response to alternating electrical signals of a second frequency band different from the first frequency band and an antenna coupling for sending and receiving said signals.
    Type: Application
    Filed: September 20, 2017
    Publication date: November 14, 2019
    Applicants: Imperial Innovations Limited, Imperial Innovations Limited
    Inventors: Mohammad Reza Bahmanyar, Christopher Neil McLeod, Olive H Murphy
  • Publication number: 20190343388
    Abstract: An implantable device for deployment inside a human or animal body, the device comprising at least one sensing component arranged to respond to an electrical signal having a known frequency band and at least one antenna comprising at least one antenna pole connected to the at least one sensing component, the antenna pole comprising at least one helical coil and a connecting stem.
    Type: Application
    Filed: September 20, 2017
    Publication date: November 14, 2019
    Applicant: Imperial Innovations Limited
    Inventors: Mohammad Reza Bahmanyar, Christopher Neil McLeod, Olive H Murphy
  • Patent number: 10465271
    Abstract: A method of forming a part from sheet metal alloy is provided, for example, forming a part from aluminium alloy. The method comprises heating (A) the sheet metal alloy to a temperature at which solution heat treatment of the alloy occurs and so as to achieve solution heat treatment. The sheet is cooled (B) at least the critical cooling rate for the alloy and then placed between dies to form (C) it into or towards the part.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: November 5, 2019
    Assignees: IMPERIAL INNOVATIONS LIMITED, IMPRESSION TECHNOLOGIES LIMITED
    Inventors: George Adam, Daniel Balint, Trevor Dean, John Dear, Omer El Fakir, Alistair Foster, Jianguo Lin, Liliang Wang
  • Patent number: 10450360
    Abstract: A T cell receptor molecule (TCR) containing an alpha chain portion and a beta chain portion wherein the alpha chain portion contains three complementarity determining regions (CDRs): CDR1?: SSYSPS CDR2?: YTSAATL CDR3?: VVSPFSGGGADGLT or comprising or consisting of SPFSGGGADGLT and the beta chain portion contains three complementarity determining regions (CDRs): CDR1?: DFQATT CDR2?: SNEGSKA CDR3?: comprising SARDGGEG or comprising or consisting of RDGGEGSETQY, or wherein up to three amino acid residues in one or more CDRs are replaced by another amino acid.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: October 22, 2019
    Assignee: IMPERIAL INNOVATIONS LIMITED
    Inventors: Hans Josef Stauss, Liquan Gao, Shao-An Xue
  • Patent number: 10414772
    Abstract: Certain pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds that inhibit cycline dependent kinase (CDK) (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.) are disclosed. Pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions to inhibit CDK; to treat disorders associated with CDK such as those arising from an inappropriate activity, mutation, overexpression, or upstream pathway activation of CDK; or disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections; neurodegenerative disorders; ischaemia; renal diseases; and cardiovascular disorders are also disclosed. Optionally, the treatment further comprises simultaneous or sequential treatment with a further active agent, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: September 17, 2019
    Assignees: Imperial Innovations Limited, Emory University, Cancer Research Technology Limited
    Inventors: Alexander Bondke, Sebastian Kroll, Anthony Barrett, Matthew Fuchter, Brian Slafer, Simak Ali, Charles Coombes, James Patrick Snyder
  • Publication number: 20190247519
    Abstract: Disclosed herein are novel nucleic acid molecules which encode novel polypeptides for use in treating polyglutamine diseases such as Huntington's disease. The polypeptides of the invention exhibit reduced immunotoxity in vivo and may have utility in sustained (mid- or long-term) expression in vivo. Also disclosed are methods for the treatment of polyglutamine diseases, such as Huntington's disease and the use of nucleic acids and polypeptides of the invention in medical therapy. Gene therapy methods and compositions, such as AAV vectors for use in gene therapy methods are also disclosed.
    Type: Application
    Filed: November 4, 2016
    Publication date: August 15, 2019
    Applicants: IMPERIAL INNOVATIONS LIMITED, FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA
    Inventor: Mark ISALAN
  • Publication number: 20190252842
    Abstract: Apparatus and method establish quantum oscillations at room temperature. A cavity has therein a resonator structure that includes a resonant element and a gain medium. A species of the gain medium has an electronic spin multiplicity capable of supporting a two-level spin system. An optical pump pumps the resonator structure and thereby generates microwave output power through stimulated emission of thermal photons. The species of the gain medium is of a sufficiently high concentration such as to have an ensemble spin-photon coupling rate which exceeds both the cavity mode decay rate and the spin-spin decoherence rate. The optical pump pumps the resonator structure using a short pulse of nanosecond duration, or a burst of approximately a millisecond in duration at relatively low instantaneous optical power, to excite said species of the gain medium into a spin-polarized two-level system that exhibits quantum oscillations in the microwave output power.
    Type: Application
    Filed: September 14, 2017
    Publication date: August 15, 2019
    Applicants: Imperial Innovations Limited, UCL BUSINESS PLC
    Inventors: Jonathan David Baxendale BREEZE, Enrico SALVADORI, Chris KAY
  • Publication number: 20190248956
    Abstract: The present disclosure relates to the provision of novel biodegradable amphiphilic peptides and peptide analogues based derivatives comprising hydrophobic chains and their use in the permeabilization of mammalian cells and delivery of agents, for example therapeutic agents, imaging agents and cell preservation agents.
    Type: Application
    Filed: February 15, 2019
    Publication date: August 15, 2019
    Applicant: Imperial Innovations Limited
    Inventors: Rongjun Chen, Siyuan Chen, Liwei Wu
  • Publication number: 20190240282
    Abstract: The invention provides nanocages, and in particular to protein nanocages, and especially ferritin nanocages. The invention extends to variant ferritin polypeptides and their encoding nucleic acids, mutant ferritin nanocages, and their uses in diagnostics and drug delivery, as well as in phenotypic screens in drug development.
    Type: Application
    Filed: October 19, 2017
    Publication date: August 8, 2019
    Applicant: IMPERIAL INNOVATIONS LIMITED
    Inventors: Geoffrey Baldwin, James Field
  • Patent number: 10364317
    Abstract: The invention relates to novel conjugated polymers containing one or more units based on dithieno[3,2-c;2?,3?-e]azepine-4,6-dione that is fused to further aromatic rings, to methods for their preparation and educts or intermediates used therein, to polymer blends, mixtures and formulations containing them, to the use of the polymers, polymer blends, mixtures and formulations as organic semiconductors in, or for the preparation of, organic electronic (OE) devices, especially organic photovoltaic (OPV) devices and organic photodetectors (OPD), and to OE, OPV and OPD devices comprising, or being prepared from, these polymers, polymer blends, mixtures or formulations.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: July 30, 2019
    Assignees: Merck Patent GmbH, IMPERIAL INNOVATIONS LIMITED
    Inventors: Nicolas Blouin, William Mitchell, Martin Heeney, Jessica Shaw
  • Publication number: 20190207227
    Abstract: This invention relates to aqueous ink compositions comprising an aqueous solvent, particles comprising a metal or a metal compound or a mixture thereof, a dispersant, preferably selected from an electrostatic dispersant, a steric dispersant, an ionic dispersant, a non-ionic dispersant or a combination thereof, a polymeric binder and a non-ionic surfactant which may be used for 3D inkjet printing components, primarily for high-temperature electrochemical devices.
    Type: Application
    Filed: June 21, 2017
    Publication date: July 4, 2019
    Applicant: Imperial Innovations Limited
    Inventors: Geoffrey KELSALL, Lisa KLEIMINGER, Nicholas FARANDOS